© 2000 American Heart Association, Inc.
Molecular Medicine |
De Novo Expression of Macrophage Migration Inhibitory Factor in Atherogenesis in Rabbits
From the Guangdong Provincial Cardiovascular Institute (S.-G.L., X.-Y.Y.), Guangzhou, China; Department of Medicine (Y.-X.C., X.R.H., C.-P.L., H.Y.L.), The University of Hong Kong, China; and Picower Institute for Medical Research (C.M., R.B.), Manhasset, NY.
Correspondence to Hui Y. Lan, MD, PhD, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong. E-mail hylan{at}hkucc.hku.hk
Abstract—Macrophage migration inhibitory factor (MIF) has been shown to play an important role in macrophage-mediated diseases. We investigate the potential role of MIF in atherogenesis using a hypercholesterolemic rabbit model. New Zealand White rabbits fed with a 2% cholesterol diet developed hypercholesterolemia and early fatty streaks at 1 month. The lesions became advanced at 3 months and were associated with de novo MIF expression by vascular endothelial cells (VECs) and smooth muscle cells (SMCs), as demonstrated by immunohistochemistry, reverse transcriptase–polymerase chain reaction, and in situ hybridization. By contrast, there was no increase in MIF levels in rabbits fed a normal diet. In early atherogenesis, marked upregulation of MIF mRNA and protein by VECs and some intimal cells were closely associated with CD68+ monocyte adhesion onto and subsequent migration into subendothelial space. Of significance, the accumulation of macrophages was exclusively localized to areas of strong MIF expression, which may be associated with the macrophage-rich fatty streak lesion formation. Upregulation of MIF by SMCs is transient during atherogenesis. Importantly, strong MIF expression by activated macrophages may be responsible for the development of foam cell-rich lesions. Finally, the ability of MIF to induce intercellular adhesion molecule-1 expression by VECs implicates its pathogenic role in atherogenesis. In conclusion, the present study provides the first demonstration that MIF is markedly upregulated during atherogenesis. Upregulation of MIF by VECs and SMCs may play a role in macrophage adhesion, transendothelial migration, accumulation, and, importantly, transformation into foam cells. Furthermore, strong MIF expression by macrophages may both initiate and amplify the atherogenesis process.
Key Words: atherosclerosis • migration inhibitory factor • macrophages • foam cells • smooth muscle cells • vascular endothelial cells
This article has been cited by other articles:
 |
|
 |
|
  L. Wang, O. Zis, G. Ma, Z. Shan, X. Zhang, S. Wang, C. Dai, J. Zhao, Q. Lin, S. Lin, et al. Upregulation of Macrophage Migration Inhibitory Factor Gene Expression in Stroke Stroke, March 1, 2009; 40(3): 973 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zernecke, J. Bernhagen, and C. Weber Macrophage Migration Inhibitory Factor in Cardiovascular Disease Circulation, March 25, 2008; 117(12): 1594 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kwaijtaal, A. J. van der Ven, R. van Diest, C. A. Bruggeman, F. W. H. M. Bar, T. Calandra, A. Appels, and F. C. G. J. Sweep Exhaustion is Associated With Low Macrophage Migration Inhibitory Factor Expression in Patients With Coronary Artery Disease Psychosom Med, January 1, 2007; 69(1): 68 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Amin, C. S. Haas, K. Zhu, P. J. Mansfield, M. J. Kim, N. P. Lackowski, and A. E. Koch Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NF{kappa}B Blood, March 15, 2006; 107(6): 2252 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Korshunov, T. A. Nikonenko, V. A. Tkachuk, A. Brooks, and B. C. Berk Interleukin-18 and Macrophage Migration Inhibitory Factor Are Associated With Increased Carotid Intima-Media Thickening Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 295 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Z. Kong, X.-R. Huang, X. Ouyang, J.-J. Tan, G. Fingerle-Rowson, M. Bacher, W. Mu, L. A. Scher, L. Leng, R. Bucala, et al. Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques Cardiovasc Res, January 1, 2005; 65(1): 272 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Weber, A. Schober, and A. Zernecke Chemokines: Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 1997 - 2008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. H. van Dielen, W. A. Buurman, M. Hadfoune, J. Nijhuis, and J. W. Greve Macrophage Inhibitory Factor, Plasminogen Activator Inhibitor-1, Other Acute Phase Proteins, and Inflammatory Mediators Normalize as a Result of Weight Loss in Morbidly Obese Subjects Treated with Gastric Restrictive Surgery J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4062 - 4068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Pan, G. K. Sukhova, J.-T. Yang, B. Wang, T. Xie, H. Fu, Y. Zhang, A. R. Satoskar, J. R. David, C. N. Metz, et al. Macrophage Migration Inhibitory Factor Deficiency Impairs Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice Circulation, June 29, 2004; 109(25): 3149 - 3153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, M. Sakuma, A. C. Zago, X. Zhang, C. Shi, L. Leng, Y. Mizue, R. Bucala, and D. I. Simon Evidence for a Role of Macrophage Migration Inhibitory Factor in Vascular Disease Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 709 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schober, J. Bernhagen, M. Thiele, U. Zeiffer, S. Knarren, M. Roller, R. Bucala, and C. Weber Stabilization of Atherosclerotic Plaques by Blockade of Macrophage Migration Inhibitory Factor After Vascular Injury in Apolipoprotein E-Deficient Mice Circulation, January 27, 2004; 109(3): 380 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-M. Yu, K. W.-H. Lai, Y.-X. Chen, X.-R. Huang, and H. Y. Lan Expression of Macrophage Migration Inhibitory Factor in Acute Ischemic Myocardial Injury J. Histochem. Cytochem., May 1, 2003; 51(5): 625 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Muller, E. Shagdarsuren, J.-K. Park, R. Dechend, E. Mervaala, F. Hampich, A. Fiebeler, X. Ju, P. Finckenberg, J. Theuer, et al. Immunosuppressive Treatment Protects Against Angiotensin II-Induced Renal Damage Am. J. Pathol., November 1, 2002; 161(5): 1679 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fukuzawa, J. Nishihira, N. Hasebe, T. Haneda, J. Osaki, T. Saito, T. Nomura, T. Fujino, N. Wakamiya, and K. Kikuchi Contribution of Macrophage Migration Inhibitory Factor to Extracellular Signal-regulated Kinase Activation by Oxidative Stress in Cardiomyocytes J. Biol. Chem., July 5, 2002; 277(28): 24889 - 24895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takahashi, J. Nishihira, M. Shimpo, Y. Mizue, S. Ueno, H. Mano, E. Kobayashi, U. Ikeda, and K. Shimada Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes Cardiovasc Res, December 1, 2001; 52(3): 438 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-A. Lehr, T. A. Sagban, C. Ihling, U. Zahringer, K.-D. Hungerer, M. Blumrich, K. Reifenberg, and S. Bhakdi Immunopathogenesis of Atherosclerosis: Endotoxin Accelerates Atherosclerosis in Rabbits on Hypercholesterolemic Diet Circulation, August 21, 2001; 104(8): 914 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Takahashi, J. Nishihira, Y. Takahashi, U. Ikeda, and K. Shimada Letter to the Editor Circ. Res., March 2, 2001; 88 (4): e31 - e31. [Full Text] [PDF]
|
|
|
|
|
|
A. Burger-Kentischer, H. Goebel, R. Seiler, G. Fraedrich, H. E. Schaefer, S. Dimmeler, R. Kleemann, J. Bernhagen, and C. Ihling Expression of Macrophage Migration Inhibitory Factor in Different Stages of Human Atherosclerosis Circulation, April 2, 2002; 105(13): 1561 - 1566. [Abstract] [Full Text] [PDF]
|
|